Skip to main content

Day: January 31, 2024

Treasure Global to Report Second Quarter Fiscal Year 2024 Results on February 14, 2024

Hosts conference call on Thursday, February 15, 2024 NEW YORK and KUALA LUMPUR, Malaysia, Jan. 31, 2024 (GLOBE NEWSWIRE) — Treasure Global Inc (NASDAQ: TGL) (“TGL” or the “Company”), an innovative technology solutions provider, today announced that it will report its financial results for the second quarter of fiscal year 2024, which ended on December 31, 2023, after market close on Wednesday, February 14, 2024.    The Company will host a conference call and audio webcast the next morning, Thursday, February 15, 2024, at 8:30 a.m. Eastern Time featuring remarks by Sam Teo, Chief Executive Officer of TGL and Michael Chan, Chief Financial Officer of TGL.Event: Treasure Global Second Quarter Fiscal Year 2024 Results Conference CallDate: Thursday, February 15, 2024Time: 8:30 a.m. Eastern TimeLive Call: +1-877-704-4453 (Toll...

Continue reading

Morris State Bancshares Announces Solid Earnings in 2023 and Increases Quarterly Dividend

DUBLIN, Ga., Jan. 31, 2024 (GLOBE NEWSWIRE) — Morris State Bancshares, Inc. (OTCQX: MBLU) (the “Company”), the parent of Morris Bank (the “Bank”), today reported its financial results for the quarter and year ended December 31, 2023. Year over year and quarter by quarter comparisons are included herewith. On January 24, 2024, the Company’s Board of Directors declared a quarterly cash dividend of $0.46 per common share payable on or about March 15, 2024, to all shareholders of record as of February 15, 2024. This represents an increase of $0.02 per share, or 4.5%, from the quarterly dividend levels paid to shareholders in 2023. “Morris Bank delivered another year of strong financial performance despite the Fed’s continued tighter monetary policy. We made net earnings of $19.3 million in 2023, compared to $21.1 million in 2022. As...

Continue reading

Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024. Please contact your BTIG representative if you would like to schedule a virtual or in-person meeting with Bionano during the conference. For more information about the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference please refer to the BTIG website. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the...

Continue reading

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

There are no FDA-approved treatments for female sexual arousal disorder SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting advancement of Sildenafil Cream, 3.6% (Sildenafil Cream) for the treatment of female sexual arousal disorder (FSAD) to a Phase 3 clinical study. The Company also provided an update on focus areas for 2024. Progressing Towards Sildenafil Cream Phase 3 Pivotal Study The Company and the FDA aligned on key elements of the Phase 3 program to support a New Drug Application (NDA)...

Continue reading

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value. “We are pleased with the progress we have made in advancing our cardiovascular portfolio, most importantly progressing istaroxime in clinical trials in cardiogenic shock, as well as the recently announced licensing deal with Lee’s Pharmaceuticals for the Greater China-Asia Pacific region. We believe this non-dilutive licensing deal along with significantly cutting cash burn and the agreement for the elimination of the...

Continue reading

Westwood Holdings Group, Inc. to Host Fourth Quarter and Fiscal Year 2023 Conference Call/Webcast

DALLAS, Jan. 31, 2024 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE:WHG) will release its fourth quarter and fiscal year 2023 earnings after the close of the New York Stock Exchange on Wednesday, February 14, 2024. Following the release, the Company will host a live audio webcast and conference call at 4:30 pm Eastern Time (3:30 pm Central Time). To join the conference call, please register here: https://register.vevent.com/register/BI67285b888a794244b24e58e42389eca5. After registering, you will be provided with a dial-in number containing a personalized PIN. Webcast Link: https://edge.media-server.com/mmc/p/rbn4eokhDate: February 14, 2024 Time: 4:30 PM ETListen via Internet: westwoodgroup.com/investor-relations/events-webcasts Westwood Holdings Group, Inc. is an investment management boutique and wealth management...

Continue reading

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

Appointment effective February 12 following Nadim Yared’s retirement Hykes currently serves as Augmedics’ President and CEO, and has served on CVRx’s Board of Directors since 2022MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company’s new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company’s Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes’ appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplished medical device industry executive with 30 years’ experience commercializing novel therapies around the globe and has a deep understanding...

Continue reading

CymaBay Therapeutics to Participate in Upcoming Investment Conferences

NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates’ 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global Biopharma Conference, March 11-13, in Miami, Florida.Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceDate:   Wednesday, February 7th, 2024Time:   1:00pm Eastern Time, Fireside ChatWebcast:   http://ir.cymabay.com/events     Raymond James & Associates’ 45th Annual Institutional Investors...

Continue reading

LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced its participation in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, being held February 13-14, 2024 at the Cliff Lodge in Snowbird, Utah. Management will hold one-on-one meetings throughout the conference. About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase...

Continue reading

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

Company to participate in fireside chats at Guggenheim’s 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5 BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.